Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/31/2025

Evolution of Substance Use Disorder Diagnosis

Comparative Analysis of DSM and ICD Systems

  • The World Health Organization's ICD-10 maintained separate categories for mental and behavioral disorders related to substance use, with 11 disorder groupings and traditional categorical classification 1, 2, 3, 4
  • The ICD-11 chapter expanded from 11 to 21 disorder groupings, with substance dependence remaining the "master diagnosis" and introducing dimensional assessments for some disorders 1, 2, 3, 4, 5
  • The ICD-11 revision prioritized global applicability, scientific validity, and clinical utility through the largest participative process in classification history, with field studies demonstrating higher reliability and clinical utility of ICD-11 compared to ICD-10 1, 2, 6
  • ICD-11 allows for optional dimensional assessments for select disorders, providing a more nuanced approach to diagnosis 1, 5

Dimensional Assessment and Diagnostic Thresholds

  • ICD-11 introduced dimensional assessments for some disorders while maintaining categorical structure, with category-specific thresholds for diagnosis 1, 2, 5
  • The World Health Organization's ICD-11 maintains a dependence-focused approach, with substance dependence as the master diagnosis and a narrower diagnostic net compared to DSM-5-TR 1, 2, 3, 4, 5

Diagnostic Criteria for Substance Use Disorders

Core Diagnostic Differences

  • The American Psychiatric Association's DSM-5-TR uses a single dimensional "substance use disorder" diagnosis with severity grading, while the World Health Organization's ICD-11 retains the traditional separation between "harmful substance use" and "substance dependence" as distinct diagnostic categories 7

DSM-5-TR Diagnostic Approach

  • The DSM-5-TR eliminated the distinction between "abuse" and "dependence," combining them into one disorder called "substance use disorder" with 11 criteria, requiring at least 2 of 11 criteria met within a 12-month period 7, 8
  • Severity is determined purely by criterion count: mild (2-3 criteria), moderate (4-5 criteria), or severe (6+ criteria) 8, 9
  • The DSM-5-TR added "craving" as a new criterion based on factor analyses showing all criteria form a single unidimensional continuum 8

Diagnostic Thresholds and Criteria

  • The DSM-5-TR two-criterion threshold for any substance use disorder diagnosis is lower than traditional dependence thresholds, potentially capturing a broader population 7
  • The 11 criteria remain as individual items that are counted separately 7

Comparative Analysis of DSM-5-TR and ICD-11 for Substance Use Disorders

Diagnostic Structure and Criteria

  • The American Psychiatric Association's DSM-5-TR has a single unified "substance use disorder" diagnosis with 11 criteria based on data from over 200,000 participants, eliminating the problematic abuse/dependence dichotomy, and providing a dimensional severity grading (mild: 2-3 criteria, moderate: 4-5 criteria, severe: 6+ criteria) 10, 11
  • The World Health Organization's ICD-11 maintains substance dependence as the "master diagnosis," preserving the well-validated dependence syndrome concept that demonstrated consistently high reliability and validity in DSM-IV, with a narrower diagnostic approach that maintains better specificity and reduces false-positive diagnoses 10

Dimensional Assessment and Concordance

  • DSM-5-TR's integrated severity grading provides systematic gradation of disorder severity, and its criterion validity is supported by factor analyses demonstrating all criteria form a single unidimensional continuum, with the added craving criterion 10
  • ICD-11 underwent the largest participative revision in classification history, with demonstrated higher reliability and clinical utility compared to ICD-10, and preserves the clinically meaningful distinction between harmful use and dependence with empirical support 10

Clinical Utility and Validation

  • DSM-5-TR overcame the poor reliability and validity of the former abuse diagnosis, and its excellent concordance with ICD-10 and DSM-IV (all κ ≥ 0.9) supports its clinical utility 10
  • The development and validation of biomarkers to supplement self-report criteria in DSM-5-TR can improve diagnostic objectivity, and longitudinal studies examining outcomes (mortality, morbidity, quality of life) across the mild severity range can validate the clinical significance of the disorder 10

Shared Improvements Needed

  • Establishing formal harmonization working groups to align diagnostic thresholds and improve concordance, particularly for mild/harmful use categories, can enhance the clinical utility of both systems 10
  • Developing shared biomarker standards and neurobiological assessment tools for both systems can improve diagnostic accuracy, and prioritizing longitudinal outcome studies examining mortality, morbidity, treatment response, and quality of life can validate the clinical utility of both approaches 10

Evolution of Diagnostic Criteria for Sedative‑Hypnotic‑Related Disorders

DSM‑III (American Psychiatric Association)

  • DSM‑III introduced a symptom‑based specification that prioritized reliability over validity and established separate “abuse” and “dependence” categories with polythetic‑categorical diagnostic criteria. 12

Cross‑Cultural Measurement Issues

  • Measurement equivalence problems across cultural groups may generate apparent epidemiological variation that does not reflect true prevalence differences, indicating a limitation in cross‑cultural diagnostic comparability. 12, 13, 14

ICD‑10 (World Health Organization)

  • ICD‑10 retained distinct categories for substance‑related mental and behavioral disorders within 11 disorder groupings, preserving the traditional separation between harmful use and dependence. 15

ICD‑11 (World Health Organization) – Major Revision

  • ICD‑11 represents the largest participative revision in classification history, expanding disorder groupings from 11 to 21 and showing higher reliability and clinical utility than ICD‑10 in field studies (strong evidence). 15, 16
  • Substance dependence remains the “master diagnosis” in ICD‑11, preserving the well‑validated dependence‑syndrome concept with a narrower, more specific diagnostic approach. 15
  • ICD‑11 maintains the traditional separation between “harmful substance use” and “substance dependence,” contrasting with DSM‑5‑TR’s unified substance‑use disorder model. 15
  • Optional dimensional symptom qualifiers (severity ratings – mild, moderate, severe – and remission status) were introduced, allowing a dimensional layer to be applied regardless of etiology while the system stays primarily categorical. 15, 16
  • The revision prioritized global applicability, scientific validity, and clinical utility through extensive stakeholder collaboration, reflecting a consensus‑based development process. 15, 16
  • ICD‑11 eliminated a separate disorder grouping for childhood/adolescence‑onset disorders, redistributing these cases across other groupings to emphasize developmental continuity across the lifespan. 15

REFERENCES

8

DSM-5 Alcohol Use Disorder Diagnostic Criteria [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

9

Methamphetamine Use Disorder Diagnosis and Classification [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025